Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

NCT05119179 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how a diabetes medication called GLP-1 affects blood sugar control in Mexican-American adults with prediabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 300 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2021-11 · est. completion 2026-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05119179 ↗

Description as written by the study sponsor.

This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.

Treatments tested

Semaglutide also known as Ozempic Drug

Glucagon-like Peptide 1 Receptor Agonist

Main thing measured	Mean change in beta cell responsivity
Sponsor	The University of Texas Health Science Center, Houston
Conditions studied	PreDiabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05119179 ↗